Coverage to include serial monitoring in all subtypes, including hormone receptor-positive, HER2-positive, and triple negative breast cancers AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) that Natera’s Signatera molecular residual disease (MRD) test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer.

IRVINE, Calif. & AMSTERDAM & MÖNCHENGLADBACH, Germany--(BUSINESS WIRE)--Agendia, Inc., a leader in gene expression profiling for early-stage breast cancer, today announced the first patient has been enrolled in the PROOFS Registry trial.

Pan-cancer policy from Blue Shield of California covers adjuvant, recurrence monitoring, and treatment monitoring Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.

• Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapy¹ and endocrine therapy²
• Confirms Agendia’s unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for reducing the overtreatment of many women without impacting outcomes

Private cord blood company, Smart Cells, has released their 20th sample of stem cells collected from cord blood and tissue to a patient to treat autism. This is the company's first sample to be released and infused for the condition. This release closely coincides with World Autism Awareness Day on the 2nd April, for which Smart Cells have released a simple informational guide on autism for parents.

Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit.

IRVINE, CA, AMSTERDAM, NETHERLANDS - 30 November 2017 - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping Test. A total of eleven posters and discussions are being presented at SABCS, which will take place at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 5-9, 2017.

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay's intermediate range.
Physicians changed their treatment decisions in approximately 34% of all cases and in 76% of cases where treatment decisions were discordant based on the indication of the MammaPrint test, with 79% of physicians having greater confidence in their recommendation with the added clarity of MammaPrint when the 21-gene assay yielded an intermediate result.
Findings reinforce the recent ASCO Breast Cancer Guideline update which recommends the exclusive use of MammaPrint in clinically high risk and lymph node positive (1-3) patients.

ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy. ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive early-stage breast cancer patients and marks the fourth positive international guideline update for MammaPrint in 2017, recognizing the highest level of clinical evidence provided by MINDACT.